Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeffrey Skolnik, MD
AstraZeneca
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Vancouver, British Columbia, Canada
- Research Site
Toronto, Ontario, Canada
- Research Site
San Francisco, California, United States
- Research Site
Stanford, California, United States
- Research Site
Atlanta, Georgia, United States
- Research Site
Boston, Massachusetts, United States
- Research Site
Rochester, Minnesota, United States
- Research Site
Omaha, Nebraska, United States
- Research Site
New York, New York, United States
- Research Site
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2009
- Primary completion
- 30 Apr 2010
- Completion
- 30 Apr 2010
- Last update posted
- 19 Sept 2016
- Registered enrollment
- 18
- Registry id
- NCT00798096
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.